Evidence Base for VELCADE Builds as new Data is Presented at 53rd American ... PR Newswire UK (press release) Analyses of the phase 3 LYM3001 trial identified biomarker combinations present in a third of patients offering a significant progression free survival benefit with bortezomib-rituximab vs rituximab (median 14.2 vs 8.4 months, p=0.0003) and an ... |
